Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict nerve damage from common chemo drug

NCT ID NCT06490159

Knowledge-focused Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study investigates whether a blood test can predict which stomach cancer patients will develop nerve damage (peripheral neuropathy) from the chemotherapy drug paclitaxel. Paclitaxel is a standard second-line treatment for advanced gastric cancer, but nerve damage is a common and troublesome side effect. Researchers aim to develop a liquid biopsy assay to identify high-risk patients before treatment, enabling more personalized and safer chemotherapy choices. The study enrolls 150 adults with unresectable or recurrent gastric cancer who have progressed on first-line therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Paclitaxel
What this could lead to
If successful, this could lead to a simple blood test that identifies patients at high risk for nerve damage before starting paclitaxel, allowing doctors to choose safer treatments.
What could go wrong
This is an early-stage observational study focused on prediction, not treatment. The blood test may not prove accurate enough for clinical use, and it does not prevent or cure neuropathy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2018

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients need second-line chemotherapy with unresectable or recurrent Gastric cancer.

Ages

20 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. unresectable or recurrent Gastric cancer (GC) histologically confirmed to be primary adenocarcinoma of the stomach. 2. age over 20 years. 3. Eastern Cooperative Oncology Group performance status score of 0-2. 4. written informed consent following full study information is provided to the patient. 5. progression or intolerance for first-line chemotherapy comprising fluorinated pyrimidine and platinum anticancer drugs (cisplatin or oxaliplatin) for advanced GC. 6. presence of evaluable lesions as confirmed using a computed tomography (CT) or magnetic resonance imaging. Exclusion Criteria: 1. Patients with a life expectancy of shorter than 3 months 2. Patients with severe complications (angina pectoris, myocardial infarction, or arrhythmia) or uncontrollable diabetes mellitus, blood hypertension, or bleeding tendency. 3. Patients with a history of serious allergic reactions or serious drug allergy. 4. Patients with a clinically relevant mental disorder that prohibits response to questionnaires. 5. Patients for whom the attending physician considered that enrollment in the study is inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced peripheral neuropathy Gastric cancer Paclitaxel Ramucirumab

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kawasaki Medical University

    RECRUITING

    Kurashiki, Okayama-ken, 7010192, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.